Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Trulieve Cannabis's Enterprise Value for the quarter that ended in Jun. 2026 was €1,769.8 Mil.
Trulieve Cannabis's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-234.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trulieve Cannabis EV-to-EBIT Related Terms
Trulieve Cannabis EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Trulieve Cannabis's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F09 vs ANIP, XERS, HROW: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Trulieve Cannabis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trulieve Cannabis EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Trulieve Cannabis's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Trulieve Cannabis's EV-to-EBIT falls into.
Trulieve Cannabis's current Enterprise Value is €1,893.1 Mil.
Trulieve Cannabis's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-234.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trulieve Cannabis (FRA:F09) has a EV-to-EBIT of -8.07 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trulieve Cannabis and its competitors. According to the industry distribution chart, Trulieve Cannabis ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Trulieve Cannabis' EV-to-EBIT too high?
Trulieve Cannabis' current EV-to-EBIT is -8.07. Based on the distribution chart, Trulieve Cannabis ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Trulieve Cannabis has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Trulieve Cannabis' EV-to-EBIT compare to ANIP and XERS?
According to the Drug Manufacturers industry distribution chart, Trulieve Cannabis ranks #999999 out of 687 companies for EV-to-EBIT. This places Trulieve Cannabis in the lower half of its industry. The industry median EV-to-EBIT is 15.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trulieve Cannabis and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trulieve Cannabis's current EV-to-EBIT is -8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trulieve Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Trulieve Cannabis (FRA:F09) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.96, compared to a current price of €9.03 — trading 51.5% above its estimated fair value. The current EV-to-EBIT is -8.07. Trulieve Cannabis' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Trulieve Cannabis (FRA:F09), the current EV-to-EBIT is -8.07 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trulieve Cannabis (FRA:F09) Overvalued in 2026?
Based on GuruFocus' analysis, Trulieve Cannabis stock appears to be overvalued.
The current stock price of €9.03 is trading 51.5% above its estimated GF Value™ of €5.96.
GuruFocus considers Trulieve Cannabis to be Significantly Overvalued.
Key valuation signals for FRA:F09:
EV-to-EBIT: -8.07
GF Value™: €5.96 vs. price of €9.03 (51.5% above fair value)
No single metric tells the full story. See the FRA:F09 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.
65GF Score
Get the complete analysis for FRA:F09
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F09 has been successfully added to your 
